[go: up one dir, main page]

WO2007075798A3 - Méthodes et systèmes d'administration de corticostéroïdes à dépôt pulmonaire accru - Google Patents

Méthodes et systèmes d'administration de corticostéroïdes à dépôt pulmonaire accru Download PDF

Info

Publication number
WO2007075798A3
WO2007075798A3 PCT/US2006/048628 US2006048628W WO2007075798A3 WO 2007075798 A3 WO2007075798 A3 WO 2007075798A3 US 2006048628 W US2006048628 W US 2006048628W WO 2007075798 A3 WO2007075798 A3 WO 2007075798A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
systems
methods
corticosteroids
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/048628
Other languages
English (en)
Other versions
WO2007075798A2 (fr
WO2007075798A9 (fr
Inventor
Malcolm R Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tika Lakemedel AB
Original Assignee
Tika Lakemedel AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tika Lakemedel AB filed Critical Tika Lakemedel AB
Priority to EP06848786A priority Critical patent/EP1971349A2/fr
Priority to JP2008547495A priority patent/JP2009520821A/ja
Publication of WO2007075798A2 publication Critical patent/WO2007075798A2/fr
Publication of WO2007075798A9 publication Critical patent/WO2007075798A9/fr
Anticipated expiration legal-status Critical
Publication of WO2007075798A3 publication Critical patent/WO2007075798A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes et des systèmes d'administration d'un corticostéroïde, lesquels systèmes comprennent (1) un mélange aqueux inhalable, composé d'un corticostéroïde et d'un agent améliorant la solubilité, et (2) un nébuliseur pour inhalation, l'administration du mélange aqueux contenant le corticostéroïde au moyen du nébuliseur permettant d'obtenir un meilleur profil pharmacocinétique du corticostéroïde par rapport à des traitements par inhalation classiques.
PCT/US2006/048628 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes à dépôt pulmonaire accru Ceased WO2007075798A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06848786A EP1971349A2 (fr) 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes à dépôt pulmonaire accru
JP2008547495A JP2009520821A (ja) 2005-12-20 2006-12-19 肺内沈着の増大を有するコルチコステロイドを送達するための方法およびシステム

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US75233205P 2005-12-20 2005-12-20
US75276505P 2005-12-20 2005-12-20
US75273505P 2005-12-20 2005-12-20
US60/752,765 2005-12-20
US60/752,332 2005-12-20
US60/752,735 2005-12-20
US77399806P 2006-02-15 2006-02-15
US77399906P 2006-02-15 2006-02-15
US60/773,999 2006-02-15
US60/773,998 2006-02-15
US82009406P 2006-07-21 2006-07-21
US82009606P 2006-07-21 2006-07-21
US82009206P 2006-07-21 2006-07-21
US60/820,092 2006-07-21
US60/820,094 2006-07-21
US60/820,096 2006-07-21

Publications (3)

Publication Number Publication Date
WO2007075798A2 WO2007075798A2 (fr) 2007-07-05
WO2007075798A9 WO2007075798A9 (fr) 2007-08-23
WO2007075798A3 true WO2007075798A3 (fr) 2008-11-20

Family

ID=38218568

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2006/048735 Ceased WO2007075859A2 (fr) 2005-12-20 2006-12-19 Systèmes et méthodes d'administration de corticostéroïdes à dépôt pulmonaire accru
PCT/US2006/048927 Ceased WO2007075963A2 (fr) 2005-12-20 2006-12-19 Systèmes et méthodes d'administration de corticostéroïdes
PCT/US2006/048631 Ceased WO2007075801A2 (fr) 2005-12-20 2006-12-19 Méthode et système d'administration de corticostéroïdes présentant un meilleur profil pharmacocinétique
PCT/US2006/048629 Ceased WO2007075799A2 (fr) 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes présentant un meilleur profil pharmacocinétique
PCT/US2006/048630 Ceased WO2007075800A2 (fr) 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes
PCT/US2006/048628 Ceased WO2007075798A2 (fr) 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes à dépôt pulmonaire accru

Family Applications Before (5)

Application Number Title Priority Date Filing Date
PCT/US2006/048735 Ceased WO2007075859A2 (fr) 2005-12-20 2006-12-19 Systèmes et méthodes d'administration de corticostéroïdes à dépôt pulmonaire accru
PCT/US2006/048927 Ceased WO2007075963A2 (fr) 2005-12-20 2006-12-19 Systèmes et méthodes d'administration de corticostéroïdes
PCT/US2006/048631 Ceased WO2007075801A2 (fr) 2005-12-20 2006-12-19 Méthode et système d'administration de corticostéroïdes présentant un meilleur profil pharmacocinétique
PCT/US2006/048629 Ceased WO2007075799A2 (fr) 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes présentant un meilleur profil pharmacocinétique
PCT/US2006/048630 Ceased WO2007075800A2 (fr) 2005-12-20 2006-12-19 Méthodes et systèmes d'administration de corticostéroïdes

Country Status (5)

Country Link
EP (6) EP1971348A2 (fr)
JP (6) JP2009520827A (fr)
BR (1) BRPI0620225A2 (fr)
CA (2) CA2634398A1 (fr)
WO (6) WO2007075859A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US7973929B2 (en) * 2007-11-16 2011-07-05 Particle Measuring Systems, Inc. System and method for calibration verification of an optical particle counter
AR073796A1 (es) * 2008-10-10 2010-12-01 Schering Corp Formulaciones de corticosteroides y sus metodos de tratamiento
WO2015109201A1 (fr) * 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Formulation de cyclodextrine-budésonide
BR112016022405A2 (pt) * 2014-03-28 2017-08-15 Univ Liege Composições de ciclodextrina e derivado de budesonida e métodos
EP2923702A1 (fr) * 2014-03-28 2015-09-30 Universite De Liege Composition de cyclodextrine avec des dérivés de budésonide pour le traitement et la prévention d'une maladie inflammatoire pulmonaire
WO2019217286A1 (fr) 2018-05-07 2019-11-14 Prana Biosciences Inc Formulations de métaxalone
IL320395A (en) 2019-01-03 2025-06-01 Cyclarity Therapeutics Inc Cyclodextrin dimers, compositions thereof, and uses thereof
CN113491677B (zh) * 2020-03-18 2023-09-26 南京知和医药科技有限公司 一类药用抗病毒药物吸入剂新型制剂及制备方法
US20240189244A1 (en) * 2021-04-09 2024-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20050009795A1 (en) * 2000-12-04 2005-01-13 Bernard Cuenoud Mixtures or organic compounds for the treatment of airway diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
DE60113731T2 (de) * 2001-01-31 2006-06-29 Pfizer Products Inc., Groton Als inhibitoren von pde4-isozymen geeignete etherderivate
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
CN1905870A (zh) * 2003-11-21 2007-01-31 康宾纳特克斯公司 用于治疗炎性病症的方法和试剂
WO2005065649A1 (fr) * 2003-12-31 2005-07-21 Cydex, Inc. Formulation inhalable contenant de l'ether sulfoalkyle g-cyclodextrine et un corticosteroide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20050009795A1 (en) * 2000-12-04 2005-01-13 Bernard Cuenoud Mixtures or organic compounds for the treatment of airway diseases

Also Published As

Publication number Publication date
JP2009524590A (ja) 2009-07-02
WO2007075963A2 (fr) 2007-07-05
WO2007075859A2 (fr) 2007-07-05
EP1971348A2 (fr) 2008-09-24
CA2634398A1 (fr) 2007-07-05
EP1971349A2 (fr) 2008-09-24
EP1971346A2 (fr) 2008-09-24
WO2007075800A3 (fr) 2008-11-20
WO2007075799A3 (fr) 2009-01-15
JP2009520827A (ja) 2009-05-28
JP2009520822A (ja) 2009-05-28
EP1971345A2 (fr) 2008-09-24
WO2007075799A2 (fr) 2007-07-05
CA2634413A1 (fr) 2007-07-05
JP2009520821A (ja) 2009-05-28
WO2007075800A2 (fr) 2007-07-05
WO2007075801A3 (fr) 2008-12-31
EP1973550A2 (fr) 2008-10-01
JP2009520828A (ja) 2009-05-28
WO2007075798A2 (fr) 2007-07-05
BRPI0620225A2 (pt) 2011-11-01
WO2007075801A2 (fr) 2007-07-05
JP2009520823A (ja) 2009-05-28
WO2007075798A9 (fr) 2007-08-23
EP1971347A2 (fr) 2008-09-24
WO2007075859A3 (fr) 2008-12-11
WO2007075963A3 (fr) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2007075859A3 (fr) Systèmes et méthodes d'administration de corticostéroïdes à dépôt pulmonaire accru
WO2005074990A3 (fr) Procedes de prevention et de traitement du sras au moyen de compositions a faible ph pour les voies respiratoires
WO2004078144A3 (fr) Composes diphenylethylene et leurs utilisations
WO2007053698A3 (fr) Methodes de reduction de la liberation massive, induite par l'alcool, des formes posologiques orales a liberation soutenue d'opioides
WO2008053221A3 (fr) Procédé chimique
WO2005116086A3 (fr) Glucosamine et promédicaments mutuels anti-inflammatoires, compositions et procédés à base de glucosamine
WO2005067893A3 (fr) Compositions pharmaceutiques contenant du midazolam dans une concentration elevee
TN2012000446A1 (en) Pyridine and pyrazine derivative for the treatment of cf
WO2007042035A3 (fr) Therapie de combinaison pour le traitement d'un trouble auto-immun et/ou inflammatoire et de conditions associees
WO2007136439A3 (fr) Procédés, systèmes et compositions d'hyperporalisation
WO2008025787A3 (fr) Composés organiques destines au traitement de maladies inflammatoires ou des syndromes obstructifs
WO2009137378A3 (fr) Administration séquentielle d’agents de chimiothérapie pour le traitement du cancer
PL1845994T3 (pl) Kombinacja związków metyloksantyny i steroidów do leczenia przewlekłych chorób układu oddechowego
EP4245368A3 (fr) Prévention et traitement de la migraine
WO2008048589A3 (fr) Composés et procédés pour le traitement du virus de l'hépatite c
WO2006117300A3 (fr) Formes cristallines de bromure de tiotropium
WO2006117299A3 (fr) Formes cristallines de bromure de tiotropium
WO2007098106A3 (fr) Délivrance d'interféron-tau dans les voies respiratoires
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2007133944A3 (fr) Administration topique d'acyclovir
WO2009019598A3 (fr) Thérapie par inhalation pour des troubles respiratoires
WO2006026747A3 (fr) Composes de diphenylethylene et leurs utilisations
WO2006028963A3 (fr) Composes heterocycliques substitues et leurs utilisations
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone
WO2006088903A3 (fr) Composes pyrazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008547495

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006848786

Country of ref document: EP